- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07510919
CGM en el Ictus Isquémico Agudo (SENSTROKE)
Monitorización Continua de Glucosa para el Manejo Mejorado de la Hiperglucemia en Personas con Diabetes Tipo 2 Sometidas a Terapia Endovascular para Accidente Cerebrovascular Isquémico Agudo: un Ensayo Controlado Aleatorizado.
The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management.
This study is designed as a multicenter, non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management in two stroke centers in the Netherlands. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose >10 mmol/L) during the first 72 hours of hospitalization.
Researchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients.
Participants will:
- Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management
- Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization
- Receive glucose management according to the assigned monitoring strategy, based on a standardized insulin correction scheme applied uniformly across all participating centers
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Peter R van Dijk, MD PhD
- Número de teléfono: +316 88 624 50 00
- Correo electrónico: p.r.van.dijk@isala.nl
Ubicaciones de estudio
-
-
-
Enschede, Países Bajos, 7512 KZ
- Aún no reclutando
- Medisch Spectrum Twente
-
Contacto:
- Esther van Veen
- Número de teléfono: +31 53 487 2000
- Correo electrónico: wetenschapsbureau@mst.nl
-
Investigador principal:
- Myrthe de Koning, MD PhD
-
Zwolle, Países Bajos, 8025 AB
- Reclutamiento
- Isala Zwolle
-
Contacto:
- Julia Bakker
- Número de teléfono: +3188 624 50 00
- Correo electrónico: onderzoek@isala.nl
-
Investigador principal:
- Peter van Dijk, MD PhD
-
Sub-Investigador:
- Julia Bakker
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥18 years
- Acute ischemic stroke treated with endovascular therapy (EVT)
- Type 2 diabetes mellitus, defined as one of the following:
- documented diagnosis of type 2 diabetes mellitus
- use of glucose-lowering medication
- admission plasma glucose ≥11.1 mmol/L
- HbA1c ≥48 mmol/mol (≥6.5%)
Exclusion Criteria:
- Current pregnancy
- Extensive skin infections or dermatological conditions at the intended sensor site
- Medical situations known to interfere with CGM accuracy, including:
- Hypotension defined as a systolic blood pressure <100 mmHg at 30 and 60 minutes after admission
- Dialysis treatment
- Estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m²
- Use of medications known to interfere with CGM accuracy, including:
- Acetaminophen >4 g/day
- Dopamine
- High-dose vitamin C (ascorbic acid)
- Hydroxyurea / hydroxycarbamide
- Clinically relevant pancreatic disease
- Systemic glucocorticoid therapy with a prednisone-equivalent dose >5 mg/day
- Expected admission to an intensive care unit (ICU)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: CGM-guided glucose management
Participants receive glucose monitoring using a continuous glucose monitoring (CGM) system (FreeStyle Libre 2). Glucose management during hospitalization is guided by CGM measurements and used for treatment decisions according to the hospital glucose management protocol. |
Continuous glucose monitoring using the FreeStyle Libre systems (Abbott Diabetes Care) to measure interstitial glucose levels through a subcutaneous sensor that continuously records glucose concentrations during hospitalization.
Otros nombres:
|
|
Comparador activo: POCT-guided glucose management
Participants receive standard glucose monitoring using intermittent point-of-care testing (POCT) with capillary finger-prick measurements. Glucose management during hospitalization follows the hospital glucose management protocol based on POCT values. A blinded continuous glucose monitoring sensor (FreeStyle Libre Pro iQ) is placed for data collection purposes only. CGM data are not available to the clinical team and are not used for treatment decisions. |
Intermittent glucose monitoring using point-of-care finger-prick capillary blood glucose measurements according to the hospital glucose management protocol.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time spent in hyperglycemia (>10 mmol/L)
Periodo de tiempo: During the first 72 hours of hospitalization
|
Percentage of time during hospitalization with glucose levels above 10 mmol/L measured using continuous glucose monitoring. |
During the first 72 hours of hospitalization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mortalidad por todas las causas
Periodo de tiempo: 3 meses después del accidente cerebrovascular
|
3 meses después del accidente cerebrovascular
|
|
|
Duration of hyperlgycemic episodes (>10 mmol/L)
Periodo de tiempo: During the first 72 hours of hospitalization
|
Duration of hyperglycemic episodes (>10 mmol/L) measured using continuous glucose monitoring. |
During the first 72 hours of hospitalization
|
|
Duration of hypoglycemic episodes (<3.9 mmol/L)
Periodo de tiempo: During the first 72 hours of hospitalization
|
Duration of hypoglycemic episodes (<3.9 mmol/L) measured using continuous glucose monitoring. |
During the first 72 hours of hospitalization
|
|
Time in normoglycemia (3.9-10.0 mmol/L)
Periodo de tiempo: During the first 72 hours of hospitalization
|
Percentage of time with glucose levels between 3.9-10.0 mmol/L measured using continuous glucose monitoring. |
During the first 72 hours of hospitalization
|
|
Time in hypoglycemia (<3.9 mmol/L)
Periodo de tiempo: During the first 72 hours of hospitalization
|
Percentage of time with glucose levels <3.9 mmol/L measured using continuous glucose monitoring |
During the first 72 hours of hospitalization
|
|
In-hospital complications
Periodo de tiempo: During the first 72 hours of hospitalization
|
Occurrence of in-hospital complications, including infection, symptomatic intracranial hemorrhage, and delirium during hospitalization. |
During the first 72 hours of hospitalization
|
|
Neurological recovery
Periodo de tiempo: Baseline to 24 hours post-EVT
|
Neurological recovery assessed by change in National Institutes of Health Stroke Scale (NIHSS) score (range 0-42, higher scores indicate more severe neurological deficit) from baseline to 24 hours post-EVT. Early neurological improvement is defined as a ≥4-point decrease in NIHSS score, and major neurological improvement as a ≥8-point decrease or NIHSS ≤1. |
Baseline to 24 hours post-EVT
|
|
Good functional outcome
Periodo de tiempo: 3 months post stroke
|
Good functional outcome defined as a modified Rankin Scale (mRS) score ≤2 (range 0-6, lower scores indicate better functional outcome). |
3 months post stroke
|
|
Health-related quality of life
Periodo de tiempo: 3 months post stroke
|
Health-related quality of life measured using the PROMIS-10 Global Health questionnaire (range 10-50, higher scores indicate better health-related quality of life). |
3 months post stroke
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Enfermedades metabólicas
- Trastornos del metabolismo de la glucosa
- Enfermedades Nutricionales y Metabólicas
- Accidente cerebrovascular isquémico
- Carrera
- Diabetes Mellitus, Tipo 2
- Diabetes mellitus
- Hiperglucemia
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Análisis de químicos de sangre
- Pruebas de química clínica
- Técnicas de diagnóstico, endocrino
- Monitoreo, fisiológico
- Monitoreo continuo de glucosa
Otros números de identificación del estudio
- NL009652
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .